Immunogenicity, persistence and safety study of meningococcal conjugate vaccine ACWY in toddlers
Conjugate meningococcal ACWY vaccine (Nimenrix®) has been approved by the Therapeutic Goods Administration (TGA) for use in children from 12 months of age. While it is licensed for a single-dose administration to toddlers, the study aims to find out whether a 2-dose schedule will improve the level and persistence of antibody response and also prolong the period of likely protection, and to evaluate coadministration of conjugate 13-valent pneumococcal vaccine.
Faculty Research Themes
School Research Themes
For further information about this research, please contact the research group leader.